Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25777908 | 0.93 | OXER1 (0.47) | KMOOXER1MEN1KMT2ARXFP1 | |
| SCHEMBL18126630 | 0.86 | KDM4E (0.44) | KMOOXER1MEN1KMT2ARXFP1 | |
| SCHEMBL18112889 | 0.77 | MEN1 (0.43) | OXER1MEN1KMT2APHGDH | |
| SCHEMBL18112890 | 0.77 | MEN1 (0.43) | OXER1MEN1KMT2APHGDH | |
| SCHEMBL3899804 | 0.73 | RXFP1 (0.47) | MEN1KMT2ARXFP1PHGDH | |
| SCHEMBL18126614 | 0.72 | MAOB (0.38) | OXER1MEN1KMT2A | |
| SCHEMBL18126583 | 0.72 | MEN1 (0.38) | MEN1KMT2ARXFP1PHGDH | |
| SCHEMBL25776739 | 0.72 | CYP3A4 (0.39) | MEN1KMT2A | |
| SCHEMBL18126629 | 0.71 | PPARG (0.57) | KMOOXER1PPARGPPARDPPARA | |
| SCHEMBL22005144 | 0.71 | ACLY (0.52) | KMOOXER1MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | HTR5A, EDNRA, HTR3E | KMO 104/4885OXER1 27/4885MEN1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.